RxDoctor Payments Data

Nadia Bowling, MD

Clinical Neurophysiology · Granger, INNPI 1992167746

Payments from drug & device makers

$4,026in general payments, 2019–2025

Across 234 payments — averaging $17.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Argenx US, Inc.$379
  • Novartis$272
  • UCB, Inc.$262
  • Catalyst Pharmaceuticals, Inc.$209
  • Abbott$134
  • plus $936 from 16 others

What the payments were for

  • Food & beverage$4,026100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few clinical neurophysiology providers in Indianato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$88,618
Medicare patients
299
Services billed
2,559

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5013$393,621
BriviactBrivaracetam21$35,098
Nurtec OdtRimegepant Sulfate27$26,336
Emgality PenGalcanezumab-Gnlm18$18,578
Lacosamide103$9,155
TegretolCarbamazepine13$6,053
Pyridostigmine Bromide50$4,869
Carbidopa-LevodopaCarbidopa/Levodopa170$4,272
Levetiracetam128$3,550
RivastigmineRivastigmine Tartrate43$1,625
Memantine Hcl82$1,471
Propranolol Hcl ErPropranolol Hcl13$1,291
Gabapentin129$1,232
Donepezil Hcl186$1,018
Carbidopa-Levodopa ErCarbidopa/Levodopa18$938

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
UCB, Inc.Briviact$262$35,09821 claims
PfizerNurtec Odt$129$26,33627 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$19$4,86950 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few clinical neurophysiology providers in Indianaon file to place this against a meaningful peer group, so we don't.

Other clinical neurophysiology in Granger

Where these figures come from

Is this you, or does something look wrong? →